FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for OZURDEX (dexamethasone intravitreal implant) from Allergan, Inc., resulting in labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema Following Retinal Vein Occlusion
• Noninfectious Uveitis Affecting the Posterior Segment

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

SUPPL AP for OZURDEX (DEXAMETHASONE)